Reported about 23 hours ago
Barclays has initiated coverage on ABIVAX Société Anonyme (NASDAQ:ABVX) with an Overweight rating and a price target of $142. Analysts emphasize the promising risk/reward profile of investments in small and mid-cap biotechnology firms, particularly those with clinically backed data. Bharclays joins Guggenheim, which also has a Buy rating on ABIVAX with a target of $150. The company focuses on developing antiviral treatments and therapeutic vaccines for severe infectious diseases.
Source: YAHOO